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 12 
Abstract 13 
Regulating the activity of matrix metalloproteinases (MMPs) is a potential strategy for 14 
osteoarthritis (OA) therapy, although delivering this effect in a spatially and temporally 15 
localised fashion remains a challenge. Here, we report an injectable and self-healing hydrogel 16 
enabling factor-free MMP regulation and biomechanical competence in situ. The hydrogel is 17 
realised within one minute upon room temperature coordination between hyaluronic acid 18 
(HA) and a cell-friendly iron-glutathione complex in aqueous environment. The resultant gel 19 
displayed up to 300% in shear strain and tolerance towards ATDC 5 chondrocytes, in line with 20 
the elasticity and biocompatibility requirements for connective tissue application. 21 
Significantly enhanced inhibition of MMP-13 activity was achieved after 12 hours in vitro, 22 
compared with a commercial HA injection (OSTENIL® PLUS). Noteworthy, 24-hour incubation 23 
of a clinical synovial fluid sample collected from a late-stage OA patient with the reported 24 
hydrogel was still shown to downregulate synovial fluid MMP activity (100.0±17.6 % à 25 
81.0±7.5 %), with at least comparable extent to the case of the OSTENIL® PLUS-treated SF 26 
group (100.0±17.6 % à 92.3±27.3 %). These results therefore open up new possibilities in the 27 
use of HA as both mechanically-competent hydrogel as well as a mediator of MMP regulation 28 
for OA therapy.   29 
Keywords: Hyaluronic acid, iron-glutathione complex, injectable hydrogel, synovial fluid, 30 
osteoarthritis, MMP-13 inhibition.  31 
 32 
Introduction 33 
Osteoarthritis (OA) is a chronic and irreversible disease which results in continuous 34 
cartilage degradation, increased joint friction, and pain. The onset and progression of OA is 35 
closely linked to proteolytic imbalances, whereby upregulated activity of matrix 36 
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metalloproteinases (MMPs), particularly MMP-13 (collagenase), results in the pathological 37 
breakdown of articular cartilage (Yoshihara et al., 2000) (Burrage et al., 2006) (H. Li et al., 38 
2017). MMP-13 concentration strongly correlates to vascular endothelial growth factor 39 
(VEGF) concentration, which plays an important role in angiogenesis and can serve as a 40 
biomarker for OA diagnosis and therapeutic monitoring (Kim et al., 2011). In addition, the 41 
overexpression of MMP-13 is found in advanced osteoarthritic synovial fluid (Heard et al., 42 
2012). Injectable, non-cytotoxic and biomechanically viable materials that are able to inhibit 43 
MMP-13 are highly sought to restore tissue homeostasis and minimise the risks of knee 44 
replacement (M. Wang et al., 2013).  45 
Injectable materials enable the delivery and localisation of therapeutic compounds at a 46 
target diseased site. In particular, injectable materials that mimic the features of the 47 
extracellular matrix (ECM) are ideal therapeutic scaffolds since they enable cell attachment, 48 
proliferation and temporally controlled mechanical function with minimal toxic effect 49 
following degradation (Stevens & George, 2005) (Blache et al., 2020). As such, they have been 50 
widely employed as carriers for improved mesenchymal stem cell (MSC) delivery for bone 51 
repair and OA management (M. Liu et al., 2017). Hydrogel systems that contain synthetic 52 
polymers have shown promise as materials for OA management due to their injectability and 53 
versatility in presenting bioactive functionalities that downregulate MMP activity and prolong 54 
the activity of encapsulated MSCs (Clark et al., 2020). Yet, the limited degradability of many 55 
synthetic polymers and the demands of polymer synthesis make their translation to 56 
commercial products challenging. The design of injectable hydrogels from ECM-derived 57 
polymers that can correct proteolytic imbalances may provide an alternative cell-free and 58 
regulatory-friendly strategy for OA management, which avoids non-biodegradable synthetic 59 
polymers. 60 
Hyaluronic acid (HA) is an anionic non-sulfated glycosaminoglycan that constitutes one of 61 
the main components of cartilaginous ECM (Slepecky, 1967). Due to its polysaccharide 62 
backbone, a great deal of attention has been put into investigating HA functionalisation for 63 
targeted applications, aiming to accomplish tuneable physicochemical properties (Zamboni et 64 
al., 2020) and improved cell viability (Zamboni et al., 2017). However, many commercially 65 
available HA-based products are in the form of injectable materials, for instance OSTENIL® 66 
PLUS, which is routinely applied in the clinic for the treatment of osteoarthritic joints. 67 
Significantly improved knee function and pain relief were confirmed through the Visual Analog 68 
Scale (VAS) score and the Western Ontario and McMaster Universities Osteoarthritis Index 69 
(WOMAC) score (Kotevoglu et al., 2006)(Dernek et al., 2016). HA injections are usually 70 
suggested to be delivered every 1-2 weeks to the joint cavity, although they are unable to 71 
control OA-related MMP upregulation. Despite HA’s capability to interact with and stimulate 72 
chondrocytes in vivo, these products are only designed to offer a palliative, short-lived 73 
biomechanical solution that is used as a last resort prior to joint replacement. Intelligent HA 74 
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formulations that include therapeutics for OA treatment through MMP-13 inhibition, and 75 
retain mechanical stability, are highly sought. To pursue this vision, a cell-friendly iron-76 
glutathione (Fe3+-GSH) complex recently reported by our group (Gao et al., 2020) was 77 
investigated for use as both a crosslinker of HA to yield an injectable hydrogel, and as a 78 
potential therapeutic to inhibit MMP-13 activity, exploiting the competitive metal-79 
coordinating reaction between thiol complexed iron (Fe3+) and free sulfhydryl groups of active 80 
MMPs.  81 
Although some effort afforded the creation of HA-containing gels via metal coordination, 82 
e.g. INTERGELTM, unpleasant side-effects and serious complications experienced by many 83 
patients call for new safer alternatives (Tang et al., 2006). To prevent tissue damage from ·OH 84 
and peroxy-type radicals, which could be generated during hyaluronic acid degradation 85 
(Katarina Valachová et al., 2016; Katarína Valachová et al., 2015), it is important to involve 86 
reductive components into the HA-based therapeutic material, for example, thiol groups 87 
(Katarína Valachová et al., 2015).  In this case, introducing cell friendly Fe3+-GSH complex into 88 
HA hydrogels is worth investigating.  89 
Hydrogel injectability has been pursued via dynamic covalent chemistries in biopolymer-90 
based hydrogels for tissue engineering, including Schiff-base reactions (Huang et al., 2016; S. 91 
Li et al., 2020), Diels-Alder reactions (DA) click coupling reactions (Hu et al., 2019) (Spicer, 92 
2020), as well as via thermal gelation mechanisms (Zhang et al., 2019; Lee et al., 2020) 93 
compliant with injection-mediated delivery. On the one hand, the formation of covalently 94 
crosslinked hydrogels with appropriate mechanical properties in physiological conditions to 95 
reduce joint friction has up to now proven challenging. This is largely due to the fact that the 96 
presence of covalent crosslinks reduces hydrogel’s dynamic tensile, compressive and shear 97 
strain, limiting hydrogel’s ability to bear multiple load-bearing cycles, as in the case of articular 98 
cartilage. On the other hand, although thermosensitive polymer formulations have been 99 
developed, only a limited number have been made with HA formulations free of the synthetic 100 
polymer phase (Zhang et al., 2019).  101 
Other than covalent networks, redox-based self-healable and injectable polymer hydrogels 102 
were achieved that can withstand relatively high shear strain (~50 %) (Chen et al., 2019) (L. 103 
Liu et al., 2019). Likewise, metal-coordinated hybrid materials have been reported serving as 104 
electroconductive materials (Shi et al., 2015), catalyst supports (Loynachan et al., 2019), and 105 
for magnetic resonance imaging (Paquet et al., 2011) (H. Wang et al., 2019). Ultimately, 106 
composite hydrogels have been made of multiple biopolymers and bioglass and ionically 107 
crosslinked by calcium dications (Yu et al., 2019). The composite material is able to withhold 108 
quercetin, an MMP inhibitor, so that 70% reduction in MMP-13 expression was reported after 109 
48 hours, which proved key to induce cartilage repair after 12 weeks in vivo. These studies 110 
provide novel design concepts that harness the functionalities of metals and peptides, aiming 111 
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to build simple ECM mimetics with flexible mechanical properties and MMP inhibition 112 
capability. 113 
In this work, the straightforward creation of a non-toxic HA-based hydrogel that is 114 
injectable and self-healing is reported. HA combined with an iron (III)-glutathione (Fe3+-GSH) 115 
complex results in the formation of a physical hydrogel upon co-injection. We hypothesised 116 
that hydrogel-induced MMP inhibition was accomplished by harnessing the metal-117 
coordinating reaction between thiol-complexed iron(III) and the free sulfhydryl groups of 118 
active MMPs. Crucially, the Fe3+-GSH complex has the dual function of being the crosslinker 119 
within the hydrogel, and also providing a therapeutic effect for inhibiting MMP activity, as 120 
confirmed with synovial fluid clinical samples collected from patients with late-stage OA. 121 
Consequently, the hydrogel may act as a self-healable scaffold that reduces joint friction and 122 
halts cartilage degradation, whilst boosting local cell function. Delivery of this system in situ 123 
has significant potential in OA therapy, aiming to prevent the degradation of cartilage whilst 124 
correcting growth factor concentrations and cellular activity towards cartilage repair.  125 
 126 
2. Materials and methods  127 
The hyaluronic acid sodium salt (molecular weight: 1,200 kDa, cosmetic grade) was 128 
purchased from Hollyberry Cosmetic. L-glutathione (reduced) was purchased Alfa Aesar. 129 
Alamar Blue assay kit was from ThermoFisher Scientific. Human recombinant Pro-MMP 13 130 
was purchased from Antibodies.com, and the MMP activity assay kit (Fluorometric Green, 131 
ab112146) was from ABChem. All the other reagents were provided by Sigma-Aldrich. 132 
Rheology of HA solutions supplemented with Fe3+-GSH  133 
Different concentrations of Fe3+-GSH complex were added to the HA solution (Table S1) to 134 
achieve the optimal, most stable, hydrogel. To exclude the influence of HA concentration on 135 
gel formation, the final concentration of HA in the gel-forming mixture was controlled to 1.33 136 
wt.% by addition of deionised water. All test group samples were named as “Fe xxx”, in which 137 
“xxx” corresponds to the volume of Fe3+-GSH solution (µL) in the HA solution (mL). All control 138 
samples were named as “Ctrl xxx”, in which “xxx” corresponds to the volume (µL) of Fe3+-GSH 139 
solvent (120 mM HCl) per mL of HA solution. 140 
The Fe3+-GSH-supplemented HA solution was injected onto an MCR 302 Rheometer (Anton 141 
Paar) and pressed by a 25 mm parallel plate (1.5 mm gap) at 37 °C with a variable shear rate 142 
to study the viscosity of hydrogels formed with different Fe3+-GSH complex content.  143 
Preparation of Fe3+-GSH self-healing HA hydrogel (Fe 300) 144 
The Fe3+-GSH complex was prepared using our previous method (Gao et al., 2020). Briefly, 145 
123 mg (0.4 millimoles) of GSH was added to 4 mL FeCl3 aqueous solution (0.1 M), and the 146 
mixture was mildly agitated by vortex mixing for 2 min until the solution became yellow. Then, 147 
5 
 
the complex was precipitated by adding 40 mL of ethanol (×3) and collected by centrifugation 148 
at 10,000 rpm for 15 min. The Fe3+-GSH complex was dried at 37 °C for further use.  149 
10 mg of Fe3+-GSH complex was dissolved in 1 mL HCl solution (120 mM). Each 300 μL 150 
Fe3+-GSH complex solution was added to 1 mL hyaluronic acid solution (2 wt.%) and stirred at 151 
room temperature for 1 min to obtain a self-healing hydrogel (Fe3+-GSH gel). The self-healing 152 
behaviour of all hydrogels formed was characterised by determining the reversible viscosity 153 
from a low shear strain (0.01 %) for 200 s, followed by a high shear strain (500 %) 154 
measurement for 100 s at 37 °C. The testing frequency was fixed at a constant value of 5 155 
rad·s-1. Ten low-to-high shear strain cycles were measured in this process using an Anton Paar 156 
MCR 302 rheometer.  157 
Determination of hydrogel shear modulus and shear strength  158 
The shear modulus (storage modulus G’ and loss modulus G’’) of the Fe3+-GSH crosslinked 159 
hydrogel (Fe 300) was measured via a frequency sweep using an MCR 302 rheometer (Anton 160 
Paar). This method was set with a 25 mm parallel plate at 37 °C, 1.5 mm gap, from 1-100 rad/s 161 
under 5 % amplitude. G’ and G’’ were determined at 37 °C over a shear strain range of 0-500 162 
% with a constant angular frequency (5 rad·s-1). Every 1.0 mL volume of Fe3+-GSH gel was 163 
injected onto the sample plate and slightly pressed by a 25 mm parallel plate geometry with 164 
a gap of 1.5 mm. Hyaluronic acid with the same amount of HCl solution only was measured as 165 
a control for both shear modulus and shear strain. 166 
Molecular mechanism study 167 
57Fe Mössbauer spectroscopy was applied to study iron chelation and valence. 168 
Measurements were carried out using acrylic absorber discs (area: 1.8 cm2) loaded with a 169 
dried gel sample to achieve a Mössbauer thickness of 1. The 14.4 keV γ-rays were supplied by 170 
the cascade decay of 25 mCi 57Co in Rh matrix source, oscillated at constant acceleration by a 171 
SeeCo W304 drive unit, detected using a SeeCo 45431 Kr proportional counter operating with 172 
1.745 kV bias voltage applied to the cathode. All measurements were carried out at 293 K over 173 
a velocity range of ±6 mm·s−1, and were calibrated relative to α-Fe foil. Spectral data were 174 
fitted using the Recoil software package, using a single Lorentzian line shape necessitated by 175 
the low signal/noise ratio obtained for the sample (indicative of its low Fe content). 176 
Cellular tolerability study 177 
ATDC 5 chondrocytes were cultured (37 °C, 5% CO2) in a mixed medium of Dulbecco’s 178 
modified Eagle’s medium (DMEM) and Ham’s F12 medium (1:1 in volume), supplemented 179 
with 5% fetal bovine serum (FBS), and 1 % penicillin-streptomycin. A defined amount of self-180 
healing gel was transferred into individual wells of a 96-well-plate and diluted by cell culture 181 
medium to a final concentration of 0 µL (tissue culture plastics, TCPs), 5 µL, 10 µL, 20 µL, 30 182 
µL, 40 µL and 50 µL per well, followed by addition of 100 µL cell suspension (5×104 cells/mL) 183 
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in each (n=4). The cell viability was quantified by Alamar blue assay after 1-day, 3-day, 5-day 184 
culture. Cells cultured on TCPs were set as the control group.  185 
MMP-13 inhibition study with MMP-13–supplemented solution 186 
The self-healing gel, as well as an HA solution and a commercial HA gel for OA injection, 187 
OSTENIL® PLUS (both with the same HA concentration as the self-healing gel), were added to 188 
deionised water (×4). Then, 20 µL of each sample was added to individual wells of a 96-well 189 
plate, followed by adding 80 µL H2O per well. Pro-MMP 13 was activated following the 190 
manufacturer protocol. Briefly, 5 µL MMP-13 (10 µg MMP-13/20 µL sample) was dissolved in 191 
a p-aminophenyl mercuric acetate (AMPA) working solution (1 mM) to 1 µg/mL and then 192 
incubated at 37 °C for 40 min. Activated MMP-13 was diluted with AMPA solution (2 mM) to 193 
25 ng/mL and then immediately added into the sample wells (each containing 100 µL of the 194 
sample), corresponding to a final MMP-13 concentration of 12.5 ng/mL to cover the enzymatic 195 
concentration (6 ng/mL) recorded in synovial fluid samples of advanced OA patients (Heard et 196 
al., 2012). Deionised water with an equal volume of APMA solution (2 mM) was set as the 197 
blank, and deionised water with an equal volume of activated MMP-13 was set as the none 198 
treatment group. After 12-hour or 24-hour incubation, MMP-13 activity was quantified via 199 
fluorometric assay (Fluorometric Green, ab112146, Abcam) (Liang et al., 2018). 50 µL of each 200 
sample was pipetted into a new 96-well-plate, followed by 50 µL of MMP Green Substrate 201 
working solution. MMP 13-activity was recorded in fluorescence after 1-hour reaction in dark 202 
at 37 °C using a microplate reader (Thermo Scientific Varioskan® Flash, Ex/Em=490/525 nm).  203 
MMP-13 regulation study with patient collected synovial fluid  204 
Synovial fluid (SF) samples were collected from late-stage osteoarthritic patients at Chapel 205 
Allerton Hospital (Leeds, UK) under ethical approval granted by the National Research Ethics 206 
Committee (ethical approval number: 07/Q1205/27). SF samples were stored at -80 ˚C until 207 
use. A fluorometric assay kit (Fluorometric Green, ab112146) was used to measure the total 208 
proteolytic activity in both SF and hydrogel-incubated SF samples. SF samples were diluted 209 
with the MMP assay buffer (×4), and the final Fe3+-GSH crosslinked gel dose was increased 210 
(×4). 50 µL of diluted SF were mixed with 40 µL of Fe3+-GSH crosslinked gel, and 10 µL of 211 
deionised water was supplemented in each well to achieve a final concentration of 100 µL/mL 212 
[Fe3+-GSH crosslinked gel/solution]. The fluorometric assay was conducted after 24-hour 213 
incubation following the same assay protocol reported for MMP-13 activity measurement.  214 
Statistical analysis 215 
All the samples were tested with at least three replicates (n≥3) and presented as Mean±SD. 216 
Statistical significance level was calculated through one-way ANOVA with a p-value at 0.05. 217 
Final statistical results were presented as *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001, ****p≤0.0001.  218 
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Results and discussion 219 
Attempts to create hydrogels from HA (2 wt.%) and varying amounts of the Fe3+-GSH 220 
complex (10 mg/mL) were conducted, and the optimal hydrogel was formed from 300 μL Fe3+-221 
GSH complex (10 mg/mL) and 1 mL HA solution (2 wt.%). A significant decrease in viscosity 222 
was observed with increasing shear rate from 0.01 Hz (14,400 Pa·s) to 4 Hz (37 Pa·s), whereas 223 
the viscosity remained constant at shear rates between 4 Hz and 100 Hz (Fig. 1a). Compared 224 
with the other materials created, the stability in hydrogel viscosity suggested a balanced 225 
coordination at a Fe3+-GSH crosslinker concentration of 300 µL per mL of HA solution. On the 226 
other hand, in the HA solution control groups, replacement of the Fe-GSH complex with the 227 
HCl solution resulted in significantly lower viscosity(Fig. 1b), whereby no significant viscosity 228 
variation was observed across the control groups. 229 
 230 
Fig. 1 Flow curve of aqueous solutions supplemented with (a) either varied Fe3+-GSH complex/HA ratio 231 
or (b) varied concentration of HA, enlarged within the red box. 232 
 233 
The iron oxidation state in the optimal hydrogel (Fe 300) was ferric (Fe3+) occupying 234 
octahedral coordination (Dyar et al., 2006)) ((Khalil et al., 2013), as determined by 57Fe 235 
Mössbauer spectroscopy (Fig. 2), which also confirmed the chelation of Fe3+ to HA. The 236 
confirmed Fe3+ state in the hydrogel therefore speaks against a GSH-induced reduction to Fe2+ 237 
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and the consequent generation of toxic reactive oxygen species, supporting the safe 238 
injectability of the HA hydrogel in the OA site. In light of these characteristics, the 239 
aforementioned hydrogel Fe 300 was chosen for further investigation.  240 
 241 
 242 
Fig. 2 Fitted 57Fe Mössbauer spectrum of dry Fe3+-GSH gel at 293 K, relative to thin α-Fe foil. The clear 243 
presence of a doublet attributable to paramagnetic Fe3+ can be observed, despite the low signal/noise 244 
ratio due to the low abundance of Fe3+-GSH content in the gel. Fitted centre shift (δ) = 0.41 ± 0.02 mm 245 
s-1 and quadrupole splitting (Δ) = 0.72 ± 0.02 mm s-1 with HWHM linewidth = 0.21 ± 0.02 mm s-1. 246 
 247 
A much higher G’ value (120 Pa) was recorded for the Fe 300 gel that contained the Fe3+-248 
GSH crosslinker, compared to the HCl-HA control (10 Pa), again indicating that Fe-coordination 249 
to HA enables gel formation. Constant storage (G’= 120 Pa) and loss (G’’= 70 Pa) moduli of the 250 
self-healing gel were successfully measured in frequency sweep mode, confirming a 251 
predominantly elastic behaviour in the range of 1-40 rad·s-1, whilst the material elasticity was 252 
found to decrease at the increased angular frequency (Fig. 3a). Although the storage modulus 253 
is reduced compared to the chemically crosslinked HA hydrogel (G’=300 Pa), the elastic range 254 
was much greater (angular frequency: 1-10 rad·s-1) compared to the latter care  (Gao et al., 255 
2019). This behaviour illustrates the homogeneous nature of the gel. Conversely, the HCl-HA 256 
control sample presented an obvious decrease in moduli from high to low frequency (Fig. 3b).  257 
 258 
Fig. 3 Shear modulus of Fe3+-GSH hydrogel (a) and ctrl 300 samples (b) recorded during the frequency 259 
sweep.  260 
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Fig. 4 reveals the variability of dynamic shear modulus under shear strain (0.01-500 %) for 261 
the Fe3+-GSH crosslinked gel. A predominantly elastic gel response was observed up to 300 % 262 
shear strain, whereby both the storage and loss moduli remained constant when up to 80 % 263 
shear strain was applied with 5 rad/s (0.8 Hz) frequency.  264 
 265 
Fig. 4 Shear modulus of Fe3+-GSH gel measured via strain sweep. 266 
These results demonstrate mechanical compliance of the hydrogel with the ranges of shear 267 
strain (up to 1 %) and frequency (0.5-2.0 Hz) observed in vivo in both connective and fatty 268 
tissues (Yoo et al., 2011). In line with previous results, the storage modulus of the Fe3+-GSH 269 
coordinated gel was found to be greater (105 Pa) than that of the hyaluronic acid control (70 270 
Pa, Fig. S1), demonstrating increased mechanical competence.  271 
After 10 cycling tests from low shear strain to high strain, Fe3+-GSH crosslinked gels 272 
presented a stable complex viscosity in the range of 37-42 Pa·s and 12-16 Pa·s, respectively 273 
(Fig. 5 blue).  274 
 275 
Fig. 5 Dynamic time-dependent viscosity measurement of the initial (blue) and degraded (grey) 276 
Fe3+-GSH gel. 277 
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This dynamic reversible property confirms that Fe3+-GSH crosslinked gels are self-healing 278 
materials. The profound degradability of Fe3+-GSH crosslinked hydrogel in aqueous solution 279 
was confirmed by the decreased viscosity to 0.1-10 Pa·s after being incubated at 37 °C for 5 280 
days (Fig. 5 grey). The transition from the HA solution to the Fe3+-GSH crosslinked self-healing 281 
hydrogel was presented in Fig. 6a&b. Fig. 6c reveals the injectable property of this self-healing 282 
hydrogel, and the fact that the material can be absorbed (step 1) by a syringe and then be 283 
injected through the syringe tip (step 2), before undergoing extensive elongation (step 3).  284 
 285 
Fig. 6 Illustration of Fe3+-GSH hydrogel formation. (a): Molecular configuration and physical 286 
appearance of the HA solution; (b): Proposed coordination structure within, and physical appearance 287 
of, the Fe3+-GSH hydrogel. (c): Macroscopic properties of Fe3+-GSH gel, being loaded up (step 1), 288 
injected (step 2) and stretched (step 3).  289 
 290 
We could also observe the sticky property of this self-healing hydrogel in step 3; in line with 291 
previous viscosity analysis, the adhesive properties of HA were enhanced by Fe3+-GSH 292 
induction. This feature is key to enable confined application and adhesion of the gel to 293 
cartilage, aiming to stabilise the joint cavity and to reduce bone-to-bone friction, which is 294 
essential to preserve the cartilage interface (Abubacker et al., 2018). 295 
The dose of Fe3+-GSH crosslinked HA gel that is tolerated by ATDC 5 chondrocytes was then 296 
determined in vitro via Alamar Blue assay (Fig. 7). As expected, the hydrogel reveals a dose-297 
dependent impact on cellular metabolic activity.  At day 1, the lower dose (e.g. 5 and 10 µL) 298 
of Fe3+-GSH crosslinked HA gel did not show significant effect compared to the case of the 299 
TCPs control group (p > 0.05). However, the high dose groups (e.g. > 20 µL) significantly 300 
reduced the metabolic activity of ATCD-5 cells compared to the control group (p ≤ 0.01, 0.001, 301 
0.001, 0.05, respectively). Clearly, no significant difference in cellular activity was observed 302 
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following 1-day cell culture in either TCP or lower doses of Fe3+-GSH crosslinked hydrogel (with 303 
both 5 µL and 10 µL dose). At day 5, only the 5 µL group was well tolerated (p > 0.05), but all 304 
the other higher dose groups (e.g. > 10 µL) were significantly detrimental to the metabolic 305 
activity of the cells compared to the control group (p ≤ 0.05, 0.001, 0.0001 respectively).  306 
 307 
Fig.7 ATDC 5 cells viability when growing with Fe3+-GSH gel after day 1 and 5. No significant 308 
differences are labelled with “NS”. Significant differences are observed in each group with respect to 309 
the TCPs group at the same time point (n=4). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. 310 
 311 
Furthermore, the increase in metabolic activity recorded from day 1 to day 5 in ATDC 5 cells 312 
cultured with 5-30 µL hydrogel (Table 1) was similar to that measured in cells treated with the 313 
TCPs control group (7.9 times). This observation indicates that decreased doses (e.g. ≤ 30 µL) 314 
of Fe3+-GSH hydrogel did not affect the cell proliferation (e.g. cell doubling) in this time 315 
window, in contrast to the case where higher doses (e.g. ≥ 40 µL) were applied. Given that the 316 
initial cell seeding density (5,000 cells per well) was maintained across all hydrogel groups (5-317 
50 µl), the reduced cellular metabolic activity observed with increased gel volume (> 30 µl) is 318 




Table 1 Variation in ATDC 5 cellular activity over 5-day culture with varied hydrogel dosage. 321 
Hydrogel dosage Average cellular activity increase 
0 µl (TCP)* 7.9 
5 µL 10.5 
10 µL 7.0 
20 µL 8.8 
30 µL 7.4 
40 µL 0.1 
50 µL 0 
* Cells cultured in hydrogel-free Tissue Culture Plastic (TCP). 322 
 323 
This observation may suggest that the gels under 30 µL dose were temporarily toxic after 1-324 
day. However, the proliferation of the remaining ATDC 5 cells was not affected, an explanation 325 
which is supported by the optical microscope images of cells cultured for 1 (Fig. S2) and 5 days 326 
(Fig. S3). In contrast, no cellular tolerability was observed in both 40 and 50 µL hydrogel groups 327 
over 5 days. 328 
The capability of the Fe3+-GSH crosslinked hydrogels to inhibit proteolytic activity was then 329 
assessed, whereby MMP-13 was selected as a well-known upregulated protease in late-stage 330 
OA. By selecting MMP-13-supplemented aqueous solutions as a defined in vitro environment, 331 
incubation of Fe3+-GSH hydrogel resulted in a reduction of MMP-13 activity after 12 hours 332 
(95.7±3.4 %). A significant reduction in MMP-13 activity (92.9±1.4 %) was recorded after 24 333 
hours, compared to the positive control group (p<0.001) (Fig. 8). On the other hand, no 334 
significant activity difference was observed between MMP-13-supplemented solutions and 335 
the same solutions following incubation with either soluble, complex-free GSH (103.1±7.6 %) 336 
(Gao et al., 2020) or native HA after 24 hours (98.5±5.0 %). In OSTENIL® PLUS, no reduction in 337 
MMP-13 activity was seen after 12 hours, but a significant reduction (p<0.05) in activity was 338 
observed after 24 hours (96.1±1.7 %), with respect to the pristine MMP-13 solution. A 339 
comparison between the Fe3+-GSH crosslinked gel and OSTENIL® PLUS reveals that increased 340 
MMP-13 inhibition occurred in the presence of the Fe3+-GSH crosslinked hydrogel after 12 341 
hours (p<0.01), which was maintained after 24 hours (p<0.05). These results provide indirect 342 
evidence that the hydrogel-induced MMP-13 inhibition was achieved via chelation of 343 
respective iron sites with free sulfhydryl groups of active MMPs, rather than by complexation 344 
of the free zinc sites of active MMPs (Liang et al., 2018) with either the hydrogel’s or GSH’s 345 
sulfhydryl groups, on the one hand or HA’s carboxylic groups on the other hand. These 346 
observations support the key role played by the Fe3+-GSH complex in both hydrogel 347 





Fig.8 Variation of MMP-13 activity in MMP-13–supplemented solutions after 12-hour (a) and 24-hour 351 
(b) incubation with either the Fe3+-GSH crosslinked hydrogel, an HA solution or the OSTENIL® PLUS 352 
commercial injection. Data are presented as Mean ± SD, statistical analysis was carried out between 353 
each two groups and labelled as *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001, otherwise means no significant 354 
difference at p=0.05 level. 355 
 356 
A sample of synovial fluid (S162) collected from patients with late-stage OA was used to 357 
investigate the MMP-regulating capability of the Fe3+-GSH crosslinked gel in near-physiologic 358 
conditions, and to further corroborate the previous findings obtained for hydrogel-mediated 359 
MMP-13 inhibition in a defined in vitro environment, as the overall proteolytic activity, 360 
including MMP-1, -2, -3, -7, -8, -9 and -13, were confirmed to have increased activity in 361 
advanced OA (Yoshihara et al., 2000). Fig. 9 reveals that lower overall MMP activity and 362 
smaller standard deviations were observed for the Fe3+-GSH crosslinked gel (81.0±7.5 %) 363 
compared to the native SF group (100.0±17.6 %), with a p-value of 0.0942. Although OSTENIL® 364 
PLUS presented a lower average value of activity (92.3±27.3 %) compared to native SF 365 
(p=0.6528), a larger standard deviation was recorded for this group versus both SF and the 366 




Fig.9 Variation of MMP activity recorded in a patient collected SF sample after 24-hour incubation 369 
with either the Fe3+-GSH crosslinked hydrogel or the OSTENIL® PLUS commercial injection (n=4). The 370 
SF sample was collected from a patient (donor S162) with late-stage OA. 371 
 372 
The results obtained with the clinical SF sample in the absence of MMP activating reagents, 373 
i.e. APMA, therefore confirm the new MMP inhibition functionality introduced in the Fe3+-GSH 374 
crosslinked hydrogel. These results therefore support the use of this material as both a 375 
mechanically-competent hydrogel and as a mediator of MMP regulation for OA therapy.  The 376 
confirmation of hydrogel performance with patient collected samples also lay down new 377 
possibilities on the use of human synovial fluid for the preclinical evaluation of medical devices 378 
intended for osteoarthritis management, yet minimising reliance on animal testing. 379 
 380 
Conclusions 381 
A drug-free Fe3+-GSH crosslinked injectable hydrogel was prepared with integrated self-382 
healing and MMP inhibition functionalities. The coordination mechanism to yield the hydrogel 383 
was confirmed by shear frequency sweep tests, which revealed a storage modulus more than 384 
ten times higher than the loss modulus. 57Fe Mössbauer spectroscopy revealed that Fe was 385 
present in the hydrogel as octahedrally-coordinated Fe3+, so that risks of Fe2+-mediated ROS 386 
generation and ROS-mediated toxicity were minimised, supporting the hydrogel applicability 387 
in biological environment. The hydrogel could hold up to 300% shear strain and presented a 388 
stable complex viscosity (37-42 à 12-16 Pa·s) after 10 cycling tests from low to high strain. In 389 
vitro, the gel proved to be well tolerated by ATDC 5 chondrocytes and to support cell 390 
proliferation during a five day-culture. Furthermore, the gel demonstrated the inhibition of 391 
MMP activity after 24 hour-incubation in both an MMP-13–supplemented aqueous solution 392 
and a patient collected sample of synovial fluid, in light of the metal-coordinating reaction 393 
between thiol-complexed iron(III) and free sulfhydryl groups of active MMPs is exploited to 394 
induce MMP inhibition. These results therefore demonstrate that the hydrogel’s 395 
15 
 
biomechanical competence was successfully integrated with drug-free MMP regulation 396 
capability. The simple material design, together with the hydrogel’s injectability, and 397 
biochemical and self-healing functionalities support further development of this system for 398 
drug-free OA therapies. 399 
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Fe-coordination to HA in aqueous environment generates an injectable, self-healing and 409 
biomechanically viable gel and enables factor-free regulation of matrix metalloproteinases. 410 
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